ClinicalTrials.gg
CompletedNCT01420913Updated Aug 22, 2011

Randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetic Characteristics of Pregabalin According to Different Controlled Released Formulations in Healthy Male Subjects

A Phase 1 interventional study of Pregabalin in Healthy, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-08-22.

Sponsored by Yuhan Corporation · Phase 1, Interventional, and Screening

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this trial is to compare the pharmacokinetic characteristics of YHD1119 A, YHD1119 B, YHD1119 C and Lyrica capsule.

YHD1119 A, B, C are controlled released formulations which are made by YUHAN Corporation.

Primary endpoints are C max,ss and AUC tau. Secondary endpoints are AUC last, AUC infinity, T max,ss, t 1/2

02

Conditions studied

  • Healthy

Keywords

  • To evaluate the pharmacokinetic characteristics of Lyrica, YHD1119 A,B,C
03

In context

Lead sponsor

Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20\~45 years old, healthy adult male subject
  • >55 Kg(Body weight) and \< ideal body weight ± 20%

Exclusion criteria

Exclusion Criteria:

  • or ALT > 1.25 * Upper normal range (Lab)
  • Total > 1.5 * Upper normal range
  • Systolic BP >140 OR \<100, Diastolic BP >90 OR \<65
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Active comparator
    Lyrica capsule(Pregabalin 150mg)

    Drug: Pregabalin

  • Experimental
    YHD1119 A(Pregabalin SR 300mg)

    Drug: Pregabalin

  • Experimental
    YHD1119 B(Pregabalin SR 300mg)

    Drug: Pregabalin

  • Experimental
    YHD1119 C(Pregabalin SR 300mg)

    Drug: Pregabalin

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax,ss

    Time frame: 36 hr

  2. AUCtau

    Time frame: 36 hr

  3. Safety monitoring

    Laboratory findings Adverse event

    Time frame: 14 days

Secondary outcomes

  1. AUClast AUCinfinity Tmax,ss t1/2

    Time frame: 36 hour

  2. AUCinfinity

    Time frame: 36 hr

  3. Tmax,ss

    Time frame: 36 hr

  4. t 1/2

    Time frame: 36 hr

07

Study locations

1 site
  • Seoul ST.Mary Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2011
First posted
Aug 22, 2011
Start
Aug 2011
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Last update
Aug 22, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01420913
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Aug 22, 2011
Start date
Aug 2011
Primary completion
Aug 2011
Completion
Aug 2011
Last update
Aug 22, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion